423 related articles for article (PubMed ID: 17894058)
21. Importance of oral glucose tolerance test in patient with schizophrenia.
Margetić B; Aukst-Margetić B; Badanjak A
Psychiatr Danub; 2005 Jun; 17(1-2):94-6. PubMed ID: 16395850
[TBL] [Abstract][Full Text] [Related]
22. Clinical and toxicological profile of fluphenazine decanoate in elderly chronic schizophrenia.
Altamura AC; Mauri MC; Girardi T; Panetta B
Int J Clin Pharmacol Res; 1990; 10(4):223-8. PubMed ID: 2079381
[TBL] [Abstract][Full Text] [Related]
23. Eleven years of experience with depot neuroleptics.
Gross H; Kaltenbäck E; Pfolz H
Acta Psychiatr Belg; 1981; 81(2):128-32. PubMed ID: 6117183
[TBL] [Abstract][Full Text] [Related]
24. Relapse in chronic schizophrenics treated with fluphenazine decanoate is associated with low serum neuroleptic levels.
Jayaram G; Coyle J; Tune L
J Clin Psychiatry; 1986 May; 47(5):247-8. PubMed ID: 3700342
[TBL] [Abstract][Full Text] [Related]
25. Dose response of prophylactic antipsychotics.
Davis JM; Kane JM; Marder SR; Brauzer B; Gierl B; Schooler N; Casey DE; Hassan M
J Clin Psychiatry; 1993 Mar; 54 Suppl():24-30. PubMed ID: 8097195
[TBL] [Abstract][Full Text] [Related]
26. Depot neuroleptics: the relevance of psychosocial factors--a United States perspective.
Hogarty GE
J Clin Psychiatry; 1984 May; 45(5 Pt 2):36-42. PubMed ID: 6143746
[TBL] [Abstract][Full Text] [Related]
27. The effect of age on the pharmacological management of ambulatory patients treated with depot neuroleptic medications for schizophrenia and related psychotic disorders.
Mamo DC; Sweet RA; Chengappa KN; Reddy RR; Jeste DV
Int J Geriatr Psychiatry; 2002 Nov; 17(11):1012-7. PubMed ID: 12404650
[TBL] [Abstract][Full Text] [Related]
28. Predictors for starting depot administration of risperidone in chronic users of antipsychotics.
Vehof J; Postma MJ; Bruggeman R; De Jong-Van Den Berg LT; Van Den Berg PB; Stolk RP; Burger H
J Clin Psychopharmacol; 2008 Dec; 28(6):625-30. PubMed ID: 19011430
[TBL] [Abstract][Full Text] [Related]
29. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia.
Gitlin M; Nuechterlein K; Subotnik KL; Ventura J; Mintz J; Fogelson DL; Bartzokis G; Aravagiri M
Am J Psychiatry; 2001 Nov; 158(11):1835-42. PubMed ID: 11691689
[TBL] [Abstract][Full Text] [Related]
30. Monitoring plasma levels of fluphenazine during chronic therapy with fluphenazine decanoate.
Miller RS; Peterson GM; McLean S; Westhead TT; Gillies P
J Clin Pharm Ther; 1995 Apr; 20(2):55-62. PubMed ID: 7650075
[TBL] [Abstract][Full Text] [Related]
31. Experience with fluphenazine decanoate in the management of chronic schizophrenic outpatients.
Gaby N; Lefkowitz D; Israel JR
N C Med J; 1982 Sep; 43(9):641-4. PubMed ID: 6958987
[No Abstract] [Full Text] [Related]
32. Low neuroleptic serum levels in patients receiving fluphenazine decanoate.
Tune LE; Creese I; Coyle JT; Pearlson G; Snyder SH
Am J Psychiatry; 1980 Jan; 137(1):80-2. PubMed ID: 6101523
[TBL] [Abstract][Full Text] [Related]
33. [Characteristics of the therapeutic action fluphenzaine decanoate (moditen-depot) in schizophrenia].
Tsutsul'kovskaia MIa; Minsker EI; Panteleeva GP; Mazurskii MB; Pekunova LG
Zh Nevropatol Psikhiatr Im S S Korsakova; 1973; 73(5):753-8. PubMed ID: 4718619
[No Abstract] [Full Text] [Related]
34. [What should we recommend for schizophrenic patients: long-term drug prevention or interval treatment?].
Müller P
Nervenarzt; 1983 Sep; 54(9):477-85. PubMed ID: 6138720
[No Abstract] [Full Text] [Related]
35. A comparative study with pipothiazine palmitate and fluphenazine enanthate in the treatment of schizophrenic patients.
Jain RC; Ananth JV; Lehmann HE; Ban TA
Curr Ther Res Clin Exp; 1975 Oct; 18(4):585-9. PubMed ID: 241609
[No Abstract] [Full Text] [Related]
36. Serum neuroleptic levels and clinical outcome in schizophrenic patients treated with fluphenazine decanoate.
Brown WA; Silver MA
J Clin Psychopharmacol; 1985 Jun; 5(3):143-7. PubMed ID: 3998204
[TBL] [Abstract][Full Text] [Related]
37. [The position of the depot-neuroleptics in the therapy of chronic psychoses. Experience with fluphenazine-decanoate].
Auch W
Med Welt; 1970 Oct; 21(41):1785-8. PubMed ID: 5471981
[No Abstract] [Full Text] [Related]
38. Fluphenazine-induced neuroleptic malignant syndrome in a schizophrenic patient.
Aruna AS; Murungi JH
Ann Pharmacother; 2005 Jun; 39(6):1131-5. PubMed ID: 15840734
[TBL] [Abstract][Full Text] [Related]
39. Fluphenazine decanoate: a clinical problem?
Inderbitzin LB; Lewine RR; Gloersen BA; Rosen PB; McDonald SC; Vidanagama BP
Am J Psychiatry; 1989 Jan; 146(1):88-91. PubMed ID: 2563210
[TBL] [Abstract][Full Text] [Related]
40. Adverse extrapyramidal effects in four horse given fluphenazine decanoate.
Baird JD; Arroyo LG; Vengust M; McGurrin MK; Rodriguez-Palacios A; Kenney DG; Aravagiri M; Maylin GA
J Am Vet Med Assoc; 2006 Jul; 229(1):104-10. PubMed ID: 16817724
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
